IGKV1D-22 and cancer: Building on these discoveries, the newly utilized S100A8/A9 inhibitor biologics, including S100A8/A9 neutralizing monoclonal antibody Ab45 and SSSR decoys (comprising recombinant fusion proteins of the extracellular domains of SSSRs (exSSSRs) linked with the human IgG2 Fc region at their C-terminal ends: exSSSRs-Fc), effectively function to prevent extracellular S100A8/A9-mediated cancer metastasis (Tomonobu et al. 2020a).